Is hair loss a side effect of Tymlos (abaloparatide)? This is a question raised by some patients prescribed this daily subcutaneous injection for postmenopausal osteoporosis. Abaloparatide — marketed as Tymlos in the US and Eladynos in the EU — is a synthetic parathyroid hormone-related protein analogue that stimulates bone formation to reduce fracture risk. Based on current clinical trial data and regulatory product information, hair loss is not a recognised side effect of abaloparatide. This article explores the evidence, outlines the established side-effect profile, and explains when to seek medical advice if you notice unexpected hair changes during treatment.
Summary: Hair loss is not a recognised side effect of Tymlos (abaloparatide) based on current clinical trial data and regulatory prescribing information.
- Abaloparatide (Tymlos/Eladynos) is a PTHrP analogue used to treat postmenopausal osteoporosis by stimulating bone formation via daily subcutaneous injection.
- Hair loss (alopecia) does not appear in the US Prescribing Information or EMA product information for abaloparatide as a recognised adverse effect.
- Recognised side effects include injection site reactions, orthostatic hypotension, nausea, palpitations, hypercalciuria, and elevated serum uric acid.
- Hair thinning in postmenopausal women is commonly caused by declining oestrogen, thyroid dysfunction, iron deficiency, or vitamin D deficiency — not abaloparatide.
- Abaloparatide is not currently MHRA-licensed in Great Britain; any UK use is on an unlicensed basis under specialist oversight.
- Suspected adverse reactions, including unexpected hair loss, should be reported via the MHRA Yellow Card scheme regardless of licensing status.
Table of Contents
- Abaloparatide and Hair Loss: What the Evidence Shows
- Recognised Side Effects of Abaloparatide
- Why Some Medicines Can Cause Hair Thinning or Shedding
- When to Speak to Your GP or Specialist
- Managing Side Effects While Taking Abaloparatide
- UK Regulatory Context and Reporting Suspected Side Effects
- Frequently Asked Questions
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Abaloparatide and Hair Loss: What the Evidence Shows
Hair loss is not listed as a recognised side effect of abaloparatide in either the US Prescribing Information or EMA product information, and the pivotal ACTIVE trial did not identify it as a significant adverse event.
Experiencing these side effects? Our pharmacists can help you navigate them →
Abaloparatide (brand name Tymlos in the United States; Eladynos in the European Union) is a synthetic analogue of parathyroid hormone-related protein (PTHrP) used in the treatment of osteoporosis in postmenopausal women at high risk of fracture. It is administered as a daily subcutaneous injection and works primarily by stimulating bone formation.
Important note for UK readers: Abaloparatide is not currently licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. Any use within the UK would therefore be on an unlicensed basis, subject to appropriate clinical governance and specialist oversight. The information in this article draws on the US Prescribing Information (Tymlos) and, where applicable, the European Medicines Agency (EMA) authorisation for Eladynos.
At present, hair loss (alopecia) is not listed as a recognised side effect of abaloparatide in either the US Prescribing Information or the EMA product information for Eladynos. The pivotal ACTIVE trial (Miller PD et al., JAMA, 2016), which compared abaloparatide against placebo and teriparatide in postmenopausal women with osteoporosis, did not identify hair thinning or shedding as a statistically significant adverse event.
It is important to acknowledge that individual patient experiences can vary. Some people taking abaloparatide may notice changes in hair texture or density, but there is no established causal link between abaloparatide and hair loss based on current clinical evidence. If you are experiencing hair changes whilst taking this medicine, it is worth considering other potential contributing factors, including nutritional deficiencies, hormonal changes associated with menopause, thyroid dysfunction, or concurrent medications. Reporting such symptoms to your GP or specialist remains important, both for your own care and to contribute to ongoing pharmacovigilance.
Not sure if this is normal? Chat with one of our pharmacists →
| Side Effect | Frequency | Severity | Management |
|---|---|---|---|
| Hair loss (alopecia) | Not a recognised side effect; no causal link established | Not applicable | Investigate alternative causes (thyroid, iron, vitamin D, menopause); report via MHRA Yellow Card |
| Injection site reactions (redness, pain, bruising, swelling) | Common (ACTIVE trial) | Mild to moderate | Rotate sites, allow pen to reach room temperature, apply gentle pressure; do not rub |
| Dizziness and orthostatic hypotension | Common, especially early doses | Mild to moderate | Inject when able to sit or lie down; rise slowly; stay well hydrated |
| Nausea | Common, particularly early weeks | Mild to moderate | Administer at a consistent time daily; consult GP or pharmacist if persistent |
| Palpitations | Reported in clinical trials | Moderate; seek urgent review if severe | Contact GP promptly; seek emergency care if accompanied by chest pain or loss of consciousness |
| Hypercalciuria (elevated urinary calcium) | Reported; monitor in at-risk patients | Moderate; relevant in kidney stone history | Consult SmPC; monitor renal function and calcium in high-risk patients |
| Elevated serum uric acid | Less common | Mild to moderate; relevant in gout history | Inform prescriber if history of gout; monitor uric acid levels as clinically indicated |
Recognised Side Effects of Abaloparatide
The most commonly reported side effects of abaloparatide include injection site reactions, orthostatic hypotension, nausea, palpitations, fatigue, headache, and hypercalciuria; hair loss is not among them.
Understanding the established side-effect profile of abaloparatide helps patients and clinicians distinguish expected reactions from unexpected ones. According to the US Prescribing Information and clinical trial data from the ACTIVE trial, the most commonly reported side effects include:
-
Injection site reactions — redness, pain, bruising, or swelling at the site of injection
-
Dizziness and orthostatic hypotension — a drop in blood pressure upon standing, which can cause light-headedness, particularly with early doses
-
Nausea — particularly in the early weeks of treatment
-
Palpitations — a sensation of a racing or irregular heartbeat
-
Fatigue and headache — reported in a proportion of trial participants
-
Hypercalciuria — elevated calcium levels in the urine, which may occur and warrants consideration in patients with a history of kidney stones, pre-existing hypercalciuria, or symptoms suggestive of urinary tract problems
Less commonly, elevated serum uric acid levels have been observed, which may be relevant for patients with a history of gout. Abaloparatide carries a warning in the US Prescribing Information regarding a potential risk of osteosarcoma, based on animal studies at supratherapeutic doses; this risk has not been confirmed in humans at therapeutic doses, and the medicine is contraindicated in patients at increased baseline risk of osteosarcoma.
Hair loss does not feature among these recognised adverse effects. Patients should be reassured that its absence from the official side-effect information reflects the findings of robust clinical trials. Nevertheless, any new or unexpected symptom should be discussed with a healthcare professional, as individual responses to medicines can differ and some effects may only emerge through post-marketing surveillance.
Why Some Medicines Can Cause Hair Thinning or Shedding
Drug-related hair loss most commonly occurs via telogen effluvium, triggered two to four months after starting a new medicine, but postmenopausal women are also prone to hair thinning from hormonal, nutritional, and thyroid causes unrelated to abaloparatide.
To understand why patients may query whether abaloparatide causes hair loss, it is helpful to consider how certain medicines can affect the hair growth cycle. Hair follicles are among the most metabolically active structures in the body, making them sensitive to physiological and pharmacological changes.
The most common drug-related hair loss is telogen effluvium — a diffuse shedding that occurs when a significant number of hair follicles are prematurely pushed into the resting (telogen) phase of the growth cycle. This typically occurs two to four months after a triggering event, which can include starting a new medication, illness, surgery, or significant physiological stress. Medicines known to cause this include anticoagulants, retinoids, beta-blockers, and certain hormonal therapies.
Another mechanism is anagen effluvium, which affects actively growing hairs and is more commonly associated with chemotherapy agents, tending to produce more rapid and pronounced hair loss.
In postmenopausal women — the primary population for whom abaloparatide is prescribed — hair thinning is also a well-documented consequence of declining oestrogen levels. Female pattern hair loss (androgenetic alopecia) is additionally common in this age group and may be mistaken for a medication side effect. Conditions such as iron deficiency anaemia, thyroid dysfunction, and vitamin D deficiency are prevalent in postmenopausal women and are independent causes of hair shedding. Before attributing hair changes to abaloparatide, these alternative explanations should be carefully explored with a clinician.
For further patient-facing information on the common causes of hair loss and when to seek help, the NHS hair loss page (nhs.uk) provides a useful starting point.
When to Speak to Your GP or Specialist
Seek prompt GP review if you notice significant or sudden hair shedding, patchy loss, or hair changes accompanied by fatigue or weight changes, as these may indicate a treatable underlying cause rather than a medication effect.
Whilst hair loss is not a confirmed side effect of abaloparatide, any new symptom that develops during treatment warrants attention. Knowing when to seek medical advice helps ensure your safety and allows for timely investigation of any underlying cause.
Seek urgent medical attention (call 999 or go to A&E) if you experience:
-
Chest pain or severe palpitations accompanied by dizziness or loss of consciousness
-
Severe confusion, extreme thirst, or muscle weakness, which could indicate significant hypercalcaemia
Contact your GP or specialist promptly if you notice:
-
Significant or sudden hair shedding that is new or worsening
-
Patchy hair loss, which may suggest alopecia areata — an autoimmune condition unrelated to medication
-
Hair loss accompanied by other symptoms such as fatigue, weight changes, or skin changes, which could indicate a thyroid or nutritional problem
-
Dizziness, fainting, or palpitations, which are recognised side effects of abaloparatide requiring prompt review
-
Signs of hypercalcaemia, including excessive thirst, frequent urination, or muscle weakness
-
Any injection site reaction that does not resolve or appears infected
Your GP can arrange blood tests to check thyroid function, full blood count, ferritin, and vitamin D levels — all of which may contribute to hair loss and are treatable. It is also worth reviewing any other medications you are taking that may be temporally associated with hair shedding. If your specialist suspects the hair changes are medicine-related, they will weigh the benefits of continuing abaloparatide against the impact on your quality of life. Do not stop taking abaloparatide without first consulting your prescriber, as abrupt discontinuation may affect your bone health management plan.
Managing Side Effects While Taking Abaloparatide
Most abaloparatide side effects are manageable and diminish over time; practical measures include rotating injection sites, rising slowly to prevent dizziness, and keeping a symptom diary if hair changes occur.
For most patients, the side effects of abaloparatide are manageable and tend to diminish over time as the body adjusts to the medication. Practical strategies can help minimise discomfort and support adherence to treatment.
For injection site reactions: Allow the injection pen to reach room temperature before use, rotate injection sites regularly, and apply gentle pressure after injecting. Avoid rubbing the site, as this can worsen bruising.
For dizziness and orthostatic hypotension: Orthostatic symptoms are most likely to occur with the first several doses. It is advisable to administer the injection at a time when you are able to sit or lie down if you feel light-headed. Rising slowly from a seated or lying position can reduce the risk of falls. Staying well hydrated is also beneficial. Routine prolonged rest after every injection is not required once you have established that you tolerate the medicine well, but discuss the most suitable approach with your prescriber or pharmacist.
For nausea: Taking the injection at a consistent time each day — some patients find a particular time of day suits them better — may reduce the impact of nausea on daily activities. If nausea is persistent, your GP or pharmacist can advise on suitable options.
If you are concerned about hair changes: Keep a simple diary noting when shedding began relative to starting abaloparatide, any other new medications, dietary changes, or stressful events. This information will help your clinician identify the most likely cause. Ensuring adequate protein intake, iron, and vitamin D through diet or supplementation (as advised by your doctor) supports overall hair health.
Treatment duration: Abaloparatide, like other parathyroid hormone analogues, is generally used for a limited period — typically up to 18 to 24 months, with a cumulative limit of approximately two years across all PTH analogue therapies. After completing a course of abaloparatide, it is usual practice to transition to an antiresorptive therapy (such as a bisphosphonate) to maintain the bone density gains achieved. Your specialist will guide you on the appropriate sequencing of treatments in line with current clinical guidance, including NICE NG226 (Osteoporosis: identification, assessment and management).
Open communication with your healthcare team is key. Side effects that are well-managed are less likely to lead to unnecessary treatment discontinuation, which is important given the significant benefits abaloparatide offers in reducing fracture risk.
UK Regulatory Context and Reporting Suspected Side Effects
Abaloparatide is not MHRA-licensed in Great Britain, but suspected adverse reactions including hair loss should be reported via the MHRA Yellow Card scheme; UK prescribing is guided by NICE NG226 and specialist clinical judgement.
In the United Kingdom, the safety of medicines is monitored by the Medicines and Healthcare products Regulatory Agency (MHRA). As noted above, abaloparatide is not currently MHRA-licensed in Great Britain. It holds a marketing authorisation in the European Union under the brand name Eladynos, granted by the EMA. UK clinicians prescribing abaloparatide on an unlicensed basis should follow appropriate governance frameworks for the use of unlicensed medicines.
Regardless of licensing status, patients and healthcare professionals in the UK can — and should — report suspected adverse reactions, including any unexpected hair loss, through the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk). This reporting system is vital for detecting rare or previously unrecognised side effects that may not have been apparent during clinical trials.
When selecting bone-protective therapies for postmenopausal osteoporosis, UK clinicians are guided by NICE NG226 (Osteoporosis: identification, assessment and management) and relevant NICE technology appraisals, including TA464 (bisphosphonates for preventing fragility fractures). There is currently no NICE technology appraisal specifically for abaloparatide; prescribing decisions are therefore guided by specialist clinical judgement, individual patient assessment, and the available regulatory product information.
Patients should be provided with clear written information about their treatment, including recognised side effects and safety advice. If hair loss is not listed in the product information and you experience it, this does not mean it is impossible — it may be rare, coincidental, or related to another cause. Reporting it via the Yellow Card scheme contributes to the broader evidence base and helps protect other patients.
In summary, hair loss is not a recognised side effect of abaloparatide based on current evidence from clinical trials and regulatory product information. However, individual experiences should always be taken seriously. Working collaboratively with your GP or specialist ensures that any concerns are properly investigated and that your osteoporosis treatment continues to protect your bone health safely and effectively.
Frequently Asked Questions
Can Tymlos (abaloparatide) cause hair loss?
Hair loss is not a recognised side effect of Tymlos (abaloparatide) according to clinical trial data or official prescribing information. If you notice hair shedding whilst taking abaloparatide, it is more likely related to another cause, such as hormonal changes, nutritional deficiency, or thyroid dysfunction, and should be discussed with your GP.
What are the most common side effects of abaloparatide I should know about?
The most commonly reported side effects of abaloparatide include injection site reactions, dizziness or light-headedness upon standing (orthostatic hypotension), nausea, palpitations, fatigue, headache, and elevated calcium in the urine. These effects are generally manageable and often improve as your body adjusts to the medication.
Is Tymlos available on the NHS in the UK?
Tymlos (abaloparatide) is not currently licensed by the MHRA in Great Britain, so it is not routinely available on the NHS. It holds a marketing authorisation in the EU as Eladynos; any use in the UK would be on an unlicensed basis under specialist clinical oversight and appropriate governance frameworks.
Why is my hair thinning after starting a new osteoporosis treatment?
Hair thinning in postmenopausal women is very common and is frequently caused by declining oestrogen levels, iron deficiency, thyroid dysfunction, or vitamin D deficiency — all of which are independent of osteoporosis medication. Your GP can arrange blood tests to identify a treatable cause before attributing hair changes to any specific medicine.
How does abaloparatide differ from teriparatide for treating osteoporosis?
Both abaloparatide and teriparatide are parathyroid hormone analogues that stimulate bone formation and are used for postmenopausal osteoporosis at high fracture risk, but abaloparatide is a synthetic PTHrP analogue whereas teriparatide is a recombinant fragment of human PTH. Teriparatide (Forsteo) is MHRA-licensed and available in the UK; abaloparatide is not currently licensed in Great Britain.
How do I report a side effect I think might be caused by abaloparatide?
In the UK, you can report any suspected side effect — including unexpected hair loss — through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk; both patients and healthcare professionals can submit reports. Reporting even uncertain or rare reactions is important, as it helps the MHRA detect safety signals that may not have been identified during clinical trials.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
